These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 22046394)

  • 1. Predictors of limb fat gain in HIV positive patients following a change to tenofovir-emtricitabine or abacavir-lamivudine.
    Martin A; Amin J; Emery S; Baker D; Carr A; Cooper DA; Bloch M;
    PLoS One; 2011; 6(10):e26885. PubMed ID: 22046394
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Changes in bone turnover and bone loss in HIV-infected patients changing treatment to tenofovir-emtricitabine or abacavir-lamivudine.
    Haskelberg H; Hoy JF; Amin J; Ebeling PR; Emery S; Carr A; STEAL Study Group
    PLoS One; 2012; 7(6):e38377. PubMed ID: 22719882
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changes in fat mitochondrial DNA and function in subjects randomized to abacavir-lamivudine or tenofovir DF-emtricitabine with atazanavir-ritonavir or efavirenz: AIDS Clinical Trials Group study A5224s, substudy of A5202.
    McComsey GA; Daar ES; O'Riordan M; Collier AC; Kosmiski L; Santana JL; Fichtenbaum CJ; Fink H; Sax PE; Libutti DE; Gerschenson M
    J Infect Dis; 2013 Feb; 207(4):604-11. PubMed ID: 23204164
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hip structural parameters over 96 weeks in HIV-infected adults switching treatment to tenofovir-emtricitabine or abacavir-lamivudine.
    Haskelberg H; Pocock N; Amin J; Ebeling PR; Emery S; Carr A; ; Allworth A
    PLoS One; 2014; 9(4):e94858. PubMed ID: 24722774
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Changes in body composition and mitochondrial DNA in HIV-1-infected patients switching to fixed-dose abacavir/lamivudine or tenofovir/emtricitabine: a substudy of the BICOMBO trial.
    Curran A; Martinez E; Podzamczer D; Lonca M; Barragan P; Crespo M; Falco V; Vidal-Sicart S; Imaz A; Martinez M; Gatell JM; Ribera E
    Antivir Ther; 2012; 17(4):711-8. PubMed ID: 22374987
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SWIFT: prospective 48-week study to evaluate efficacy and safety of switching to emtricitabine/tenofovir from lamivudine/abacavir in virologically suppressed HIV-1 infected patients on a boosted protease inhibitor containing antiretroviral regimen.
    Campo R; DeJesus E; Bredeek UF; Henry K; Khanlou H; Logue K; Brinson C; Benson P; Dau L; Wang H; White K; Flaherty J; Fralich T; Guyer B; Piontkowsky D
    Clin Infect Dis; 2013 Jun; 56(11):1637-45. PubMed ID: 23362296
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of abacavir/lamivudine and tenofovir/emtricitabine among treatment-naive HIV-infected patients initiating therapy.
    Tan DH; Chan K; Raboud J; Cooper C; Montaner JS; Walmsley S; Hogg RS; Klein MB; Machouf N; Rourke SB; Tsoukas C; Loutfy MR;
    J Acquir Immune Defic Syndr; 2011 Sep; 58(1):38-46. PubMed ID: 21709570
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 96-Week results of abacavir/lamivudine versus tenofovir/emtricitabine, plus efavirenz, in antiretroviral-naive, HIV-1-infected adults: ASSERT study.
    Moyle GJ; Stellbrink HJ; Compston J; Orkin C; Arribas JR; Domingo P; Granier C; Pearce H; Sedani S; Gartland M;
    Antivir Ther; 2013; 18(7):905-13. PubMed ID: 23899468
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inflammation markers after randomization to abacavir/lamivudine or tenofovir/emtricitabine with efavirenz or atazanavir/ritonavir.
    McComsey GA; Kitch D; Daar ES; Tierney C; Jahed NC; Melbourne K; Ha B; Brown TT; Bloom A; Fedarko N; Sax PE
    AIDS; 2012 Jul; 26(11):1371-85. PubMed ID: 22546988
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HLA alleles association with changes in bone mineral density in HIV-1-infected adults changing treatment to tenofovir-emtricitabine or abacavir-lamivudine.
    Haskelberg H; Cordery DV; Amin J; Kelleher AD; Cooper DA; Emery S;
    PLoS One; 2014; 9(3):e93333. PubMed ID: 24681993
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Switching to tenofovir/emtricitabine from abacavir/lamivudine in HIV-infected adults with raised cholesterol: effect on lipid profiles.
    Behrens G; Maserati R; Rieger A; Domingo P; Abel F; Wang H; Pearce G
    Antivir Ther; 2012; 17(6):1011-20. PubMed ID: 22910324
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of bone and renal effects in HIV-infected adults switching to abacavir or tenofovir based therapy in a randomized trial.
    Rasmussen TA; Jensen D; Tolstrup M; Nielsen US; Erlandsen EJ; Birn H; Østergaard L; Langdahl BL; Laursen AL
    PLoS One; 2012; 7(3):e32445. PubMed ID: 22479327
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness and safety of simplification from tenofovir-lamivudine (TDF-3TC) to tenofovir-emtricitabine (TDF-FTC) co-formulation (Truvada) in virologically suppressed HIV-infected patients on HAART.
    Palacios R; Hidalgo C; Ríos MJ; Rivero A; Muñoz L; Lozano F; Gutiérrez-Ravé V; Gálvez MC; del Arco A; Santos J
    Eur J Clin Microbiol Infect Dis; 2009 Apr; 28(4):399-402. PubMed ID: 18841401
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudine/lamivudine and efavirenz in antiretroviral-naive patients: virologic, immunologic, and morphologic changes--a 96-week analysis.
    Pozniak AL; Gallant JE; DeJesus E; Arribas JR; Gazzard B; Campo RE; Chen SS; McColl D; Enejosa J; Toole JJ; Cheng AK
    J Acquir Immune Defic Syndr; 2006 Dec; 43(5):535-40. PubMed ID: 17057609
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The influence of HLA supertype on thymidine analogue associated with low peripheral fat in HIV.
    Cordery DV; Martin A; Amin J; Kelleher AD; Emery S; Cooper DA;
    AIDS; 2012 Nov; 26(18):2337-44. PubMed ID: 23032422
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early virologic response to abacavir/lamivudine and tenofovir/emtricitabine during ACTG A5202.
    Grant PM; Tierney C; Budhathoki C; Daar ES; Sax PE; Collier AC; Fischl MA; Zolopa AR; Balamane M; Katzenstein D
    HIV Clin Trials; 2013; 14(6):284-91. PubMed ID: 24334181
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment.
    Smith KY; Patel P; Fine D; Bellos N; Sloan L; Lackey P; Kumar PN; Sutherland-Phillips DH; Vavro C; Yau L; Wannamaker P; Shaefer MS;
    AIDS; 2009 Jul; 23(12):1547-56. PubMed ID: 19542866
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent availability of two novel, fixed formulations of antiretroviral nucleoside analogues: a 12-month prospective, open-label survey of their practical use and therapeutic perspectives in antiretroviral-naive and -experienced patients.
    Manfredi R; Calza L
    AIDS Patient Care STDS; 2008 Apr; 22(4):279-90. PubMed ID: 18290748
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy.
    Sax PE; Tierney C; Collier AC; Fischl MA; Mollan K; Peeples L; Godfrey C; Jahed NC; Myers L; Katzenstein D; Farajallah A; Rooney JF; Ha B; Woodward WC; Koletar SL; Johnson VA; Geiseler PJ; Daar ES;
    N Engl J Med; 2009 Dec; 361(23):2230-40. PubMed ID: 19952143
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tenofovir disoproxil fumarate, emtricitabine, and efavirenz compared with zidovudine/lamivudine and efavirenz in treatment-naive patients: 144-week analysis.
    Arribas JR; Pozniak AL; Gallant JE; Dejesus E; Gazzard B; Campo RE; Chen SS; McColl D; Holmes CB; Enejosa J; Toole JJ; Cheng AK
    J Acquir Immune Defic Syndr; 2008 Jan; 47(1):74-8. PubMed ID: 17971715
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.